Literature DB >> 23461611

North America and South America (NA-SA) neuropathy project.

Mamatha Pasnoor1, Osvaldo J M Nascimento, Jaya Trivedi, Gil I Wolfe, Sharon Nations, Laura Herbelin, M G de Freitas, Giseli Quintanilha, Saud Khan, Mazen Dimachkie, Richard Barohn.   

Abstract

Peripheral neuropathy is a common neurological disorder. There may be important differences and similarities in the diagnosis of peripheral neuropathy between North America (NA) and South America (SA). Neuromuscular databases were searched for neuropathy diagnosis at two North American sites, University of Kansas Medical Center and University of Texas Southwestern Medical Center, and one South American site, Federal Fluminense University in Brazil. All patients were included into one of the six major categories: immune-mediated, diabetic, hereditary, infectious/inflammatory, systemic/metabolic/toxic (not diabetic) and cryptogenic. A comparison of the number of patients in each category was made between North America and South America databases. Total number of cases in North America was 1090 and in South America was 1034 [immune-mediated: NA 215 (19.7%), SA 191 (18%); diabetic: NA 148 (13.5%), SA 236 (23%); hereditary: NA 292 (26.7%), SA 103 (10%); infectious/inflammatory: NA 53 (4.8%), SA 141 (14%); systemic/metabolic/toxic: NA 71 (6.5%), SA 124 (12%); cryptogenic: NA 311 (28.5%), SA 239 (23%)]. Some specific neuropathy comparisons were hereditary neuropathies [Charcot-Marie-Tooth (CMT) cases] in NA 246/292 (84.2%) and SA 60/103 (58%); familial amyloid neuropathy in SA 31/103 (30%) and none in NA. Among infectious neuropathies, cases of human T-lymphotropic virus type 1 (HTLV-1) neuropathy in SA were 36/141(25%), Chagas disease in SA were 13/141(9%) and none for either in NA; cases of neuropathy due to leprosy in NA were 26/53 (49%) and in SA were 39/141(28%). South American tertiary care centers are more likely to see patients with infectious, diabetic and hereditary disorders such as familial amyloid neuropathies. North American tertiary centers are more likely to see patients with CMT. Immune neuropathies and cryptogenic neuropathies were seen equally in North America and South America.

Entities:  

Mesh:

Year:  2013        PMID: 23461611     DOI: 10.3109/00207454.2013.782026

Source DB:  PubMed          Journal:  Int J Neurosci        ISSN: 0020-7454            Impact factor:   2.292


  7 in total

1.  Chronic inflammatory demyelinating polyneuropathy.

Authors:  Mazen M Dimachkie; Richard J Barohn
Journal:  Curr Treat Options Neurol       Date:  2013-06       Impact factor: 3.598

2.  Pattern-recognition approach to neuropathy and neuronopathy.

Authors:  Richard J Barohn; Anthony A Amato
Journal:  Neurol Clin       Date:  2013-05       Impact factor: 3.806

Review 3.  Cryptogenic sensory polyneuropathy.

Authors:  Mamatha Pasnoor; Mazen M Dimachkie; Richard J Barohn
Journal:  Neurol Clin       Date:  2013-03-13       Impact factor: 3.806

4.  RFC1 expansions are a common cause of idiopathic sensory neuropathy.

Authors:  Riccardo Currò; Alessandro Salvalaggio; Stefano Tozza; Chiara Gemelli; Natalia Dominik; Valentina Galassi Deforie; Francesca Magrinelli; Francesca Castellani; Elisa Vegezzi; Pietro Businaro; Ilaria Callegari; Anna Pichiecchio; Giuseppe Cosentino; Enrico Alfonsi; Enrico Marchioni; Silvia Colnaghi; Simone Gana; Enza Maria Valente; Cristina Tassorelli; Stephanie Efthymiou; Stefano Facchini; Aisling Carr; Matilde Laura; Alexander M Rossor; Hadi Manji; Michael P Lunn; Elena Pegoraro; Lucio Santoro; Marina Grandis; Emilia Bellone; Nicholas J Beauchamp; Marios Hadjivassiliou; Diego Kaski; Adolfo M Bronstein; Henry Houlden; Mary M Reilly; Paola Mandich; Angelo Schenone; Fiore Manganelli; Chiara Briani; Andrea Cortese
Journal:  Brain       Date:  2021-06-22       Impact factor: 13.501

5.  Rapid screening for inflammatory neuropathies by standardized clinical criteria.

Authors:  Chafic Karam; Louis A Tramontozzi
Journal:  Neurol Clin Pract       Date:  2016-10

6.  A Bayesian comparative effectiveness trial in action: developing a platform for multisite study adaptive randomization.

Authors:  Alexandra R Brown; Byron J Gajewski; Lauren S Aaronson; Dinesh Pal Mudaranthakam; Suzanne L Hunt; Scott M Berry; Melanie Quintana; Mamatha Pasnoor; Mazen M Dimachkie; Omar Jawdat; Laura Herbelin; Richard J Barohn
Journal:  Trials       Date:  2016-08-31       Impact factor: 2.279

Review 7.  Lumos for the long trail: Strategies for clinical diagnosis and severity staging for diabetic polyneuropathy and future directions.

Authors:  Tatsuhito Himeno; Hideki Kamiya; Jiro Nakamura
Journal:  J Diabetes Investig       Date:  2019-12-01       Impact factor: 4.232

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.